HomeNews UpdateOrganovo presents near-term value catalysts for FXR314 at Jones Trading Conference. Strong preclinical and human case for FXR314 in ulcerative colitis P2 2
Organovo presents near-term value catalysts for FXR314 at Jones Trading Conference. Strong preclinical and human case for FXR314 in ulcerative colitis P2 2
July 16, 2024
Organovo Holdings (Nasdaq: ONVO) presented its prospects and plans at the Jones Trading Healthcare Conference, focusing on FXR314its treatment for inflammatory bowel disease (IBD). Executive Chairman Keith Murphy emphasized the strong preclinical and human rationale for FXR314 in Phase 2a trials for the treatment of ulcerative colitis. The company has demonstrate the activity of FXR314 consistent results from predictive animal models and 3D human models of ulcerative colitis and Crohn’s disease. Murphy emphasized the Importance of a quick completion of the study for investors and patients, recalling the strong M&A activity in the IBDregarding Lilly’s $3.2 billion acquisition of Morphic following positive Phase 2a results. The presentation webcast can be viewed on the Jones Trading website.
Positive
Ongoing Phase 2a study for FXR314 in ulcerative colitis
Meaningful preclinical data and data from human models demonstrate the efficacy of FXR314
Potential for demonstration of significant activity in the current clinical trial
Increased M&A activity in the IBD sector, indicating potential value for ONVO
SAN DIEGO, July 16, 2024 (GLOBE NEWSWIRE) — Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical-stage biotechnology company focused on developing novel treatments for inflammatory bowel disease (IBD), including ulcerative colitis, today announced that Executive Chairman Keith Murphy presented the Company’s near- and long-term outlook and operational plans at the Jones Trading Healthcare Conference in Encinitas, Calif. The webcast was recorded and can be viewed at https://wsw.com/webcast/jones/onvo/1848798.
“FXR314 is a strong product and I encourage investors to read our latest presentation,” said Keith Murphy, Executive Chairman. “As mergers and acquisitions in the inflammatory bowel disease space continue to be strong, as evidenced by Lilly’s acquisition of Morphic for 3.2 billion dollars Following strong Phase 2a results, we are encouraged by our progress and our imminent opportunity to demonstrate the value of FXR314 in IBD in our own Phase 2a study. A rapid completion of the study is important to our investors and patients as we expect to demonstrate activity of FXR314 consistent with the strong results we saw in a highly predictive preclinical animal model, as well as the strong data demonstrating the effect of FXR314 to ameliorate aspects of disease in our 3D human models of ulcerative colitis and Crohn’s disease.”
About Organovo Organovo is a clinical-stage biotechnology company developing drugs that have demonstrated efficacy as drug development candidates in three-dimensional (3D) human tissue. The Company’s lead molecule, FXR314, is progressing to Phase 2 evaluation in inflammatory bowel disease and has potential applications in metabolic liver disease and oncology. The Company has proprietary technology to construct 3D human tissue that mimics key aspects of natural human tissue composition, architecture, function and disease. For more information, visit Organovo’s website at www.organovo.com.
Forward-looking statements All statements included in this press release that do not describe historical facts constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. These risks and uncertainties, as well as other factors, are more fully identified and described in the Company’s filings with the SEC, including its Annual Report on Form 10-K filed with the SEC on May 31, 2024, as these risk factors are updated in the Company’s most recently filed quarterly reports. and the Registration Statement on Form S-1 (File No. 333-278668), as amended. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. These cautionary statements should be considered together with any written or oral forward-looking statements that the Company may make in the future. Except as required by applicable law, including the United States securities laws, the Company does not intend to update the forward-looking statements to conform these statements to actual results, subsequent events or circumstances or to reflect the occurrence of unanticipated events.
What is the focus of Organovo’s presentation at the Jones Trading Healthcare Conference?
Organovo’s presentation focused on FXR314, the drug for the treatment of inflammatory bowel disease (IBD), and highlighted its strong preclinical and human efficacy in Phase 2a studies in ulcerative colitis.
What short-term value catalysts for Organovo (ONVO) are mentioned in the press release?
Near-term value catalysts for Organovo include the completion of the Phase 2a study for FXR314 in ulcerative colitis and the potential demonstration of its activity consistent with strong preclinical results.
How does recent M&A activity in the IBD sector impact Organovo’s prospects?
Strong M&A activity in the IBD sector, such as Lilly’s $3.2 billion acquisition of Morphic, is boosting Organovo’s progress and underscoring the potential value of its FXR314 treatment for IBD.
What evidence supports the potential efficacy of Organovo’s FXR314 in the treatment of IBD?
The potential efficacy of FXR314 is supported by strong results from highly predictive preclinical animal models as well as data demonstrating its effect on alleviating aspects of disease in 3D human models of ulcerative colitis and Crohn’s disease.
Organovo presents near-term value catalysts for FXR314 at Jones Trading Conference. Strong preclinical and human case for FXR314 in ulcerative colitis P2 2
Organovo Holdings (Nasdaq: ONVO) presented its prospects and plans at the Jones Trading Healthcare Conference, focusing on FXR314its treatment for inflammatory bowel disease (IBD). Executive Chairman Keith Murphy emphasized the strong preclinical and human rationale for FXR314 in Phase 2a trials for the treatment of ulcerative colitis. The company has demonstrate the activity of FXR314 consistent results from predictive animal models and 3D human models of ulcerative colitis and Crohn’s disease. Murphy emphasized the Importance of a quick completion of the study for investors and patients, recalling the strong M&A activity in the IBDregarding Lilly’s $3.2 billion acquisition of Morphic following positive Phase 2a results. The presentation webcast can be viewed on the Jones Trading website.
Positive
SAN DIEGO, July 16, 2024 (GLOBE NEWSWIRE) — Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical-stage biotechnology company focused on developing novel treatments for inflammatory bowel disease (IBD), including ulcerative colitis, today announced that Executive Chairman Keith Murphy presented the Company’s near- and long-term outlook and operational plans at the Jones Trading Healthcare Conference in Encinitas, Calif. The webcast was recorded and can be viewed at https://wsw.com/webcast/jones/onvo/1848798.
“FXR314 is a strong product and I encourage investors to read our latest presentation,” said Keith Murphy, Executive Chairman. “As mergers and acquisitions in the inflammatory bowel disease space continue to be strong, as evidenced by Lilly’s acquisition of Morphic for3.2 billion dollars Following strong Phase 2a results, we are encouraged by our progress and our imminent opportunity to demonstrate the value of FXR314 in IBD in our own Phase 2a study. A rapid completion of the study is important to our investors and patients as we expect to demonstrate activity of FXR314 consistent with the strong results we saw in a highly predictive preclinical animal model, as well as the strong data demonstrating the effect of FXR314 to ameliorate aspects of disease in our 3D human models of ulcerative colitis and Crohn’s disease.”
About Organovo
Organovo is a clinical-stage biotechnology company developing drugs that have demonstrated efficacy as drug development candidates in three-dimensional (3D) human tissue. The Company’s lead molecule, FXR314, is progressing to Phase 2 evaluation in inflammatory bowel disease and has potential applications in metabolic liver disease and oncology. The Company has proprietary technology to construct 3D human tissue that mimics key aspects of natural human tissue composition, architecture, function and disease. For more information, visit Organovo’s website at www.organovo.com.
Forward-looking statements
All statements included in this press release that do not describe historical facts constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. These risks and uncertainties, as well as other factors, are more fully identified and described in the Company’s filings with the SEC, including its Annual Report on Form 10-K filed with the SEC on May 31, 2024, as these risk factors are updated in the Company’s most recently filed quarterly reports. and the Registration Statement on Form S-1 (File No. 333-278668), as amended. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. These cautionary statements should be considered together with any written or oral forward-looking statements that the Company may make in the future. Except as required by applicable law, including the United States securities laws, the Company does not intend to update the forward-looking statements to conform these statements to actual results, subsequent events or circumstances or to reflect the occurrence of unanticipated events.
Contact
CORE IR
[email protected]
Source: Organovo, Inc.
FAQ
What is the focus of Organovo’s presentation at the Jones Trading Healthcare Conference?
Organovo’s presentation focused on FXR314, the drug for the treatment of inflammatory bowel disease (IBD), and highlighted its strong preclinical and human efficacy in Phase 2a studies in ulcerative colitis.
What short-term value catalysts for Organovo (ONVO) are mentioned in the press release?
Near-term value catalysts for Organovo include the completion of the Phase 2a study for FXR314 in ulcerative colitis and the potential demonstration of its activity consistent with strong preclinical results.
How does recent M&A activity in the IBD sector impact Organovo’s prospects?
Strong M&A activity in the IBD sector, such as Lilly’s $3.2 billion acquisition of Morphic, is boosting Organovo’s progress and underscoring the potential value of its FXR314 treatment for IBD.
What evidence supports the potential efficacy of Organovo’s FXR314 in the treatment of IBD?
The potential efficacy of FXR314 is supported by strong results from highly predictive preclinical animal models as well as data demonstrating its effect on alleviating aspects of disease in 3D human models of ulcerative colitis and Crohn’s disease.
Related Posts
President of CBS Studios announces Blue Bloods spinoff series
Eddie Murphy on reviving Axel Foley, fatherhood and what a return to the stage might look like
Virginia Senate takes no action against games of skill, VMSDEP returns to Richmond
About The Author
reggie